<DOC>
	<DOCNO>NCT00563251</DOCNO>
	<brief_summary>Bronchiolitis obliterans syndrome ( BOS ) , obstructive airway disease result chronic rejection , one major cause morbidity mortality long-term survivor allogeneic bone marrow transplantation ( BMT ) . Although augmentation immunosuppressive treatment might help effective treatment BOS lung transplantation . Macrolide antibiotic , license use antibacterial agent decade , find immunomodulatory property addition antibacterial activity . Low dose Azithromycin , antibiotic macrolide family , show promising result pilot study treat BOS associate lung transplantation . We propose perform prospective , randomise , double blind study test efficacy Azithromycin treat BOS BMT . Patients proven BOS BMT randomise two group base lung function parameter . One group receive low dose Azithromycin placebo provide group . Lung function serially monitor 3 month , 6 month 12 month commencement treatment drug/placebo . If Azithromycin proven effective treat BOS patient proven BOS treat drug .</brief_summary>
	<brief_title>Effectiveness Azithromycin Therapy Improvement Symptoms Lung Function Patients With Bronchiolitis Obliterans After Bone Marrow Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<criteria>Confirmed BOS post BMT Informed consent Women currently pregnant nursing Allergy macrolide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bronchiolitis obliterans bone marrow transplant recipient</keyword>
</DOC>